Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
grade F 1.5 1.35% 0.02
AEZS closed up 1.35 percent on Thursday, April 19, 2018, on 65 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical AEZS trend table...

Date Alert Name Type % Chg
Apr 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Apr 19 Spinning Top Other 0.00%
Apr 19 Weak + Overbought Other 0.00%
Apr 19 Wide Bands Range Expansion 0.00%
Apr 19 Overbought Stochastic Strength 0.00%
Apr 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.35%
Apr 18 Spinning Top Other 1.35%
Apr 18 Weak + Overbought Other 1.35%
Apr 18 Outside Day Range Expansion 1.35%
Apr 18 Wide Bands Range Expansion 1.35%

Older signals for AEZS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.75
52 Week Low 0.7816
Average Volume 122,813
200-Day Moving Average 1.9232
50-Day Moving Average 1.6407
20-Day Moving Average 1.4293
10-Day Moving Average 1.41
Average True Range 0.1023
ADX 25.52
+DI 20.14
-DI 20.83
Chandelier Exit (Long, 3 ATRs ) 1.3931
Chandelier Exit (Short, 3 ATRs ) 1.4269
Upper Bollinger Band 1.6729
Lower Bollinger Band 1.1857
Percent B (%b) 0.65
BandWidth 34.086616
MACD Line -0.0579
MACD Signal Line -0.0903
MACD Histogram 0.0324
Fundamentals Value
Market Cap 24.17 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -0.88
Price-to-Sales 28.12
Price-to-Book 6.12
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.65
Resistance 3 (R3) 1.65 1.59 1.63
Resistance 2 (R2) 1.59 1.56 1.60 1.62
Resistance 1 (R1) 1.55 1.53 1.57 1.55 1.61
Pivot Point 1.49 1.49 1.51 1.50 1.49
Support 1 (S1) 1.45 1.46 1.47 1.45 1.39
Support 2 (S2) 1.39 1.43 1.40 1.38
Support 3 (S3) 1.35 1.39 1.38
Support 4 (S4) 1.35